研究单位：[1]Chinese PLA General Hospital,Beijing,China[2]Etern BioPharma (Shanghai) Co., Ltd[3]Beijing Tongren Hospital,CMU,Beijing,China[4]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China[5]Qilu Hospital of Shandong University,Jinan,Shandong,China[6]The First Affiliated Hospital of Zhejiang university school of medicine,Hangzhou,Zhejiang,China
研究目的：
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0111 in patients with advanced solid tumors. It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study. ET0111 will be administered orally once daily (QD) in 21-day treatment cycles.
